1st Glaucoma Trial Completion

Seeing Machines Limited
10 January 2006



10 January 2006

                            SEEING MACHINES LIMITED

                      ('Seeing Machines' or 'the Company')



         NON -CONTACT OBJECTIVE GLAUCOMA DEVICE SUCCESSFULLY COMPLETES

                           FIRST MAJOR CLINICAL TRIAL



Seeing Machines Limited (AIM : SEE), a leading developer of advanced computer
based imaging software systems, announces the completion of the first major
clinical trial of its new groundbreaking technology for objective detection and
management of glaucoma, the group of eye diseases that affect peripheral vision,
often leading to permanent loss of vision.

Seeing Machines is developing a new medical device that assists clinicians to
diagnose and manage disorders of the human visual system, particularly glaucoma.
  This recent trial has demonstrated with meaningful clinical utility, that the
technology, as it stands today:

•         successfully detects the loss of visual field associated with
glaucoma, and

•         successfully differentiates between those patients with visual field
loss and those without, thus providing the basis for a reliable and accurate
diagnostic instrument.

Furthermore the trial has demonstrated significant opportunities for greatly
improving the performance of the technology from the base-line used in this
trial.

Commenting on the trial, Nick Cerneaz, Chief Executive of Seeing Machines said:

'The technical progress demonstrated in this trial has assisted Seeing Machines
in reaching a key milestone of our entire medical device development program.
Our scientific teams, led by Drs. Ted Maddess and Andrew James from the
Australian National University, have done a tremendous job so far and we are now
well advanced in the development work arising from this trial. The preparations
for the next major clinical trial aimed at testing these developments are well
underway with an anticipated start date this quarter.  We are very excited about
these results and keen to build further on them as we pursue our goal of
delivering the world's first non-contact objective test for glaucoma.'



Enquiries:
Seeing Machines Limited      Insinger de Beaufort       Parkgreen Communications
Nick Cerneaz, CEO            Simon Fox                  Justine Howarth /

                                                        Victoria Thomas
[phone]          [phone]       [phone]
www.seeingmachines.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange